US90466Y1038
© Globe Newswire
29.12.2025
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
News Preview
New PDUFA date expected in 1H 2026 within 30 days of NDA resubmission New PDUFA date expected in 1H 2026 within 30 days of NDA resubmission...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.11.2025
UNCY
LISTED
NASDAQ
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
News Preview
LOS ALTOS, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in two investor events in December....
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
News Preview
- Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
03.11.2025
UNCY
LISTED
NASDAQ
Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
News Preview
LOS ALTOS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
30.10.2025
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference
News Preview
Analysis of the data from the open-label pivotal trial of oxylanthanum carbonate (OLC) highlights that pill burden was significantly reduced in terms of both pill volume (7x) and pill count (2x) from pre-trial phosphate binder therapy Analysis of the data from the open-label pivotal trial of oxylanthanum carbonate (OLC) highlights that pill burden...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.10.2025
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End
News Preview
Cash runway into 2027, which is expected to support application resubmission, potential FDA approval, and launch of OLC Cash runway into 2027, which is expected to support application resubmission, potential FDA approval, and launch of OLC...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
UNCY
LISTED
NASDAQ
UNCY Deadline Today: Rosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”). Unicycive is a clinical-stage biotechnology company.
For more information, s...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
UNCY
LISTED
NASDAQ
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) and reminds investors of the October 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company...
Themefolio
Profiler
Peergroup
© BusinessWire
25.09.2025
UNCY
LISTED
NASDAQ
Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – UNCY
News Preview
The DJS Law Group reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. (“Unicycive” or “the Company”) (NASDAQ: UNCY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of UNCY...
Themefolio
Profiler
Peergroup
© BusinessWire
11.09.2025
UNCY
LISTED
NASDAQ
Rosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”). Unicycive is a clinical-stage biotechnology company.
For more information, s...
Themefolio
Profiler
Peergroup
© BusinessWire
18.08.2025
UNCY
LISTED
NASDAQ
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. (“Unicycive” or “the Company”) (NASDAQ: UNCY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commi...
Themefolio
Profiler
Peergroup
© BusinessWire
18.08.2025
UNCY
LISTED
NASDAQ
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) and reminds investors of the October 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
18.08.2025
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease
News Preview
Ensures Intellectual Property Protection Until 2040 Ensures Intellectual Property Protection Until 2040...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.08.2025
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
News Preview
- Type A Meeting requested with U.S. Food and Drug Administration (FDA) for resolution of the Complete Response Letter (CRL) for oxylanthanum carbonate (OLC)...
Themefolio
Profiler
Peergroup
© BusinessWire
19.07.2025
UNCY
LISTED
NASDAQ
UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. (“Unicycive” or “the Company”) (NASDAQ: UNCY) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.07.2025
UNCY
LISTED
NASDAQ
Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
News Preview
LOS ALTOS, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
News Preview
--Complete Response Letter (CRL) cited deficiencies previously identified at a third-party manufacturing vendor unrelated to Oxylanthanum Carbonate (OLC)...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.06.2025
UNCY
LISTED
NASDAQ
Unicycive Therapeutics, Inc. Announces Reverse Stock Split
News Preview
Shares Expected to Begin Trading on Split-Adjusted Basis on June 20, 2025 Shares Expected to Begin Trading on Split-Adjusted Basis on June 20, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.06.2025
UNCY
LISTED
NASDAQ
Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
News Preview
- The U.S. Food and Drug Administration (FDA) identified deficiencies at a third-party manufacturing vendor...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.05.2025
UNCY
LISTED
NASDAQ
Unicycive Therapeutics to Present at Upcoming Investor Conferences
News Preview
LOS ALTOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at two upcoming virtual investment conferences....
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2025
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders
News Preview
LOS ALTOS, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ: UNCY) (“Unicycive” or the “Company”), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced a change in the time of the 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The previously announc...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.05.2025
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
News Preview
- Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated commercial launch in late 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.04.2025
UNCY
LISTED
NASDAQ
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
News Preview
LOS ALTOS, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7,...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.03.2025
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update
News Preview
- Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2025
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science
News Preview
Large pill size, high pill burden and palatability were identified as key barriers for phosphate binder adherence Large pill size, high pill burden and palatability were identified as key barriers for phosphate binder adherence...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science
News Preview
LOS ALTOS, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that data from the Company’s oxylanthanum carbonate (OLC) Phase 1 dose escalation study in healthy volunteers...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.11.2024
UNCY
LISTED
NASDAQ
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference
News Preview
LOS ALTOS, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in two upcoming investment conferences in D...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2024
UNCY
LISTED
NASDAQ
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
News Preview
– OLC New Drug Application (NDA) Accepted by the FDA with a PDUFA Target Action Date of June 28, 2025–...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.11.2024
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
News Preview
– FDA sets PDUFA Action Date of June 28, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.10.2024
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
News Preview
– Late-Breaker Poster Presentation Highlights Favorable Safety & Tolerability of OLC –...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.10.2024
UNCY
LISTED
NASDAQ
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
News Preview
LOS ALTOS, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a fireside chat at the 2024 Maxim Healt...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2024
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024
News Preview
LOS ALTOS, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that a poster presentation on oxylanthanum carbonate (OLC) was selected for a Late-Breaker session at the Ame...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.10.2024
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers
News Preview
UNI-494 was Well-Tolerated as a Single Dose up to 160 mg and in Multiple Doses at 40 mg Twice-a-Day UNI-494 was Well-Tolerated as a Single Dose up to 160 mg and in Multiple Doses at 40 mg Twice-a-Day...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2024
UNCY
LISTED
NASDAQ
Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024
News Preview
LOS ALTOS, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a fireside chat at the virtual Lytham...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2024
UNCY
LISTED
NASDAQ
Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024
News Preview
LOS ALTOS, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company" or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will present a corporate update at the Virtual Life Scienc...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2024
UNCY
LISTED
NASDAQ
Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
News Preview
LOS ALTOS, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will present a corporate update at the H.C. Wainwright 26th...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.09.2024
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
News Preview
LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) f...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.08.2024
UNCY
LISTED
NASDAQ
Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024
News Preview
LOS ALTOS, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that three poster presentations will be delivered on the Company’s product candidates at the American Society...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.08.2024
UNCY
LISTED
NASDAQ
Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update
News Preview
– On Track to Submit OLC New Drug Application (NDA) by End of August 2024 –...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.07.2024
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)
News Preview
Ensures Intellectual Property Protection Until 2040 Ensures Intellectual Property Protection Until 2040...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.07.2024
UNCY
LISTED
NASDAQ
Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
News Preview
LOS ALTOS, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a Fireside Chat at the H.C. Wainwright 3...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.07.2024
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)
News Preview
– Patients preferred OLC more than 4 to 1 over their prior phosphate binder therapy –...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2024
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Joins Russell Microcap® Index
News Preview
LOS ALTOS, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced it was included in the Russell Microcap Index at the conclusion of the 2024 Russell US Indexes annual reconst...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.05.2024
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress
News Preview
– Results from Preclinical Model of Hyperphosphatemia Demonstrate the Relative Potency of OLC Compared to Tenapanor –...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.05.2024
UNCY
LISTED
NASDAQ
Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference
News Preview
LOS ALTOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a Fireside Chat at the virtual Lytham Par...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.05.2024
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting
News Preview
– OLC Demonstrates Bioequivalence to Lanthanum Carbonate –...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.05.2024
UNCY
LISTED
NASDAQ
Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update
News Preview
– On Track to Provide Topline Data from the Ongoing Pivotal Clinical Trial with Oxylanthanum Carbonate (OLC) in Q2 2024 –...
Themefolio
Profiler
Peergroup
© Newsfile
29.06.2022
UNCY
LISTED
NASDAQ
CEO Clip Video Highlights How Unicycive Therapeutics is Working to Improve Quality of Life for Patients Suffering from Kidney Diseases
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 29, 2022) - Business Television (BTV) chats with Shalabh Gupta, M.D., CEO of Unicycive Therapeutics Inc. (NASDQ: UNCY) to learn more about how they are developing life-changing new medicines to treat a variety of kidney diseases with significant unmet medical needs.If you cannot view the video abo...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
